Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

BMI Modulates the Effect of Thyroid Hormone on Lipid Profile in Euthyroid Adults.

Wang Y, Yin Q, Xu M, Ni Q, Wang W, Wang Q.

Int J Endocrinol. 2017;2017:8591986. doi: 10.1155/2017/8591986. Epub 2017 Aug 13.

2.

Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment.

Cao Y, Matsubara T, Zhao C, Gao W, Peng L, Shan J, Liu Z, Yuan F, Tang L, Li P, Guan Z, Fang Z, Lu X, Huang H, Yang Q.

Sci Rep. 2017 Aug 24;7(1):9307. doi: 10.1038/s41598-017-09598-z.

3.

Analysis of risk factors of rapid thyroidal radioiodine-131 turnover in Graves' disease patients.

Zhang R, Tan J, Wang R, Zhang G, Jia Q, Meng Z, Zhang Y.

Sci Rep. 2017 Aug 15;7(1):8301. doi: 10.1038/s41598-017-08475-z.

4.

Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease.

Kim HJ, Bang JI, Kim JY, Moon JH, So Y, Lee WW.

Korean J Radiol. 2017 May-Jun;18(3):543-550. doi: 10.3348/kjr.2017.18.3.543. Epub 2017 Apr 3.

5.

[Student abuse and Graves-basedow's disease: about a case].

Ntyonga-Pono MP, Nsame D.

Pan Afr Med J. 2017 Jan 12;26:15. doi: 10.11604/pamj.2017.26.15.11317. eCollection 2017. French.

6.

Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' Disease.

Nakamura H, Ide A, Kudo T, Nishihara E, Ito M, Miyauchi A.

Eur Thyroid J. 2016 Dec;5(4):253-260. doi: 10.1159/000448586. Epub 2016 Sep 6.

7.

Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.

Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN.

Thyroid. 2017 Apr;27(4):497-505. doi: 10.1089/thy.2016.0343. Epub 2017 Feb 6.

PMID:
28049375
8.

Excessive Cytosolic DNA Fragments as a Potential Trigger of Graves' Disease: An Encrypted Message Sent by Animal Models.

Luo Y, Yoshihara A, Oda K, Ishido Y, Suzuki K.

Front Endocrinol (Lausanne). 2016 Nov 14;7:144. eCollection 2016. Review.

9.

Clinical efficacy of combined rituximab treatment in a woman with severe Graves' ophthalmopathy.

Liu X, Guo H, Liu J, Shi B.

Exp Ther Med. 2016 Aug;12(2):1093-1096. Epub 2016 May 19.

10.

Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy.

Liu X, Wang S, Qin L, Qiang W, Dahal M, Fan P, Gao S, Shi B.

Exp Ther Med. 2016 Aug;12(2):901-908. Epub 2016 Jun 9.

11.

Change in Practice over Four Decades in the Management of Graves' Disease in Scotland.

Smith DM, Dutta S, Ahmed F, Thaha MA.

J Thyroid Res. 2016;2016:9697849. doi: 10.1155/2016/9697849. Epub 2016 May 30.

12.

Outcome of Radioiodine Therapy in a West African Population.

Onimode YA, Ankrah A, Adedapo KS.

World J Nucl Med. 2016 Jan-Apr;15(1):24-9. doi: 10.4103/1450-1147.167585.

13.

Factors Associated With Mortality of Thyroid Storm: Analysis Using a National Inpatient Database in Japan.

Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y.

Medicine (Baltimore). 2016 Feb;95(7):e2848. doi: 10.1097/MD.0000000000002848.

14.

Estimated glomerular filtration rate by serum creatinine or standardized cystatin C in Japanese patients with Graves׳ disease.

Suzuki Y, Matsushita K, Seimiya M, Yoshida T, Sawabe Y, Ogawa M, Nomura F.

Data Brief. 2015 Nov 24;5:1092-5. doi: 10.1016/j.dib.2015.11.023. eCollection 2015 Dec.

15.

Synthetic gene network restoring endogenous pituitary-thyroid feedback control in experimental Graves' disease.

Saxena P, Charpin-El Hamri G, Folcher M, Zulewski H, Fussenegger M.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1244-9. doi: 10.1073/pnas.1514383113. Epub 2016 Jan 19.

16.

Lithium Carbonate in the Treatment of Graves' Disease with ATD-Induced Hepatic Injury or Leukopenia.

Zheng R, Liu K, Chen K, Cao W, Cao L, Zhang H, Sun H, Liu C.

Int J Endocrinol. 2015;2015:694023. doi: 10.1155/2015/694023. Epub 2015 Oct 20.

17.

Immune thrombocytopenia and autoimmune thyroid disease: a controversial overlap.

Marta GN, de Campos FP.

Autops Case Rep. 2015 Jun 30;5(2):45-8. doi: 10.4322/acr.2015.002. eCollection 2015 Apr-Jun.

18.

Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis.

Mou P, Jiang LH, Zhang Y, Li YZ, Lou H, Zeng CC, Wang QH, Cheng JW, Wei RL.

PLoS One. 2015 Oct 15;10(10):e0139544. doi: 10.1371/journal.pone.0139544. eCollection 2015.

19.

Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves' Disease.

Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S, Dean DS, Castro MR, Fatourechi V, Gharib H, Stan MN, Branda ME, Bahn RS, Montori VM.

Thyroid. 2015 Nov;25(11):1191-8. doi: 10.1089/thy.2015.0277. Epub 2015 Oct 15. Erratum in: Thyroid. 2016 Jan;26(1):187. Castro, Regina M [Corrected to Castro, M Regina].

20.

Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea.

Kim HK, Yoon JH, Jeon MJ, Kim TY, Shong YK, Lee MJ, Kim BH, Kim IJ, Joung JY, Kim SW, Chung JH, Kang HC.

Endocrinol Metab (Seoul). 2015 Dec;30(4):475-80. doi: 10.3803/EnM.2015.30.4.475. Epub 2015 Sep 22.

Supplemental Content

Support Center